Avalo Therapeutics, Inc. (AVTX)
17.98
+0.48
(+2.74%)
USD |
NASDAQ |
Mar 02, 16:00
17.93
-0.05
(-0.28%)
After-Hours: 20:00
Avalo Therapeutics Cash from Investing (Quarterly) : -13.26M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| AbbVie, Inc. | -1.463B |
| ACADIA Pharmaceuticals, Inc. | -55.87M |
| Alnylam Pharmaceuticals, Inc. | -37.17M |
| Savara, Inc. | 21.47M |
| BioMarin Pharmaceutical, Inc. | -42.45M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -16.36M |
| Cash from Financing (Quarterly) | 14.37M |
| Free Cash Flow | -52.26M |
| Free Cash Flow Per Share (Quarterly) | -1.169 |
| Free Cash Flow to Equity (Quarterly) | -16.24M |
| Free Cash Flow to Firm (Quarterly) | -16.36M |
| Free Cash Flow Yield | -25.37% |